- Research Overview
- Chemical Biology and Medicinal Chemistry
- Chemical Biology and Medicinal Chemistry Overview
- Discovering Enzyme Substrates and Functions
- Discovering Protein Ligands to Probe and Alter Function
- Discovering Enzyme Activators
- Analyzing Mechanisms of Drug Resistance via Chemical Biology
- Analyzing Enzyme Conformational Dynamics, Substrate Binding, and Catalysis
- Effective Drug Targeting of Pathogens via Medicinal Chemistry
- Computational Chemistry and Biology
- Computational Chemistry and Biology Overview
- Modeling protein regulation via allostery and post-translational modifications
- Visualizing and integrating bioinformatics and biomolecular data
- Modeling membrane permeation to optimize pharmacokinetics
- Determining enzyme function by predicting substrate specificity
- Physical Biology
- Protein and Cellular Engineering
- Protein and Cellular Engineering Overview
- Monitoring enzyme activity and disease biomarkers
- Generating human proteome antibodies via phage display and directed evolution
- Globally analyzing and dissecting apoptosis
- Proximity tagging of protein-protein interactions
- Investigating cellular interactions in tissues
- Creating fluorescent probes targeting the genome and key bio-pathways
- De novo design of catalytic and membrane proteins
- Probing and modulating membrane proteins
Discovering Enzyme Activators
Examples of our research and methods include
Activating executioner caspases to fight cancer
Like most of the hundreds of human protease enzymes, the 12 members of the caspase family are expressed and stored as proenzymes that are activated only in the wake of specific signaling cascades.
Indeed, a subset of caspases, the executioner caspases -3, -6, and -7, are especially important to keep under control. Upon proteolytic activation by other caspases and proteases, they directly generate the protein-cleaving demolition of apoptosis—the programmed self-destruction of aberrant or unneeded cells that fails to occur in cancers and over-occurs in neuro-degenerative disease.
Department research seeks to directly and selectively activate executioner caspases via chemical probes and protein engineering to determine their specific mechanisms, contributions, and targets in the cellular implosion process. An ultimate goal would be to discover and utilize caspase activators as more direct and effective chemotherapies against cancer cells.
Discovering nanofibril scaffold mimics
Toward that end, researchers used high-throughput screening to discover and refine a synthetic compound dubbed 1541B that activates procaspase-3 with high specificity, independent of upstream signaling. 1541B induced apoptosis in multiple cell lines, including cancerous ones. Indeed, the results indicated that activation of procaspase-3 alone is sufficient to induce rapid apoptosis.
Department researchers were surprised to find that 1541B molecules self-assemble into nanofibrils. Electron microscopy revealed that procaspase-3 binds in clusters to the nanofibrils, a process that appears to mimic protein scaffolding complexes that recruit and activate upstream procaspases.
Further analysis of the mechanism found that trace amounts of active caspase-3 enzyme can cleave and activate its precursors clustered on the nanofibrils in a self-amplifying chain reaction.
Eventually, the nanofibril scaffold might be used to design other novel proenzyme activators and offers another way for researchers to manipulate and study enzyme function. In addition, the finding has implications for Alzheimer’s disease, as amyloid beta fibrils were found to similarly stimulate procaspase-3 activation and thus hasten neuronal cell death.